Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Carcinoma, Renal Cell 4 Carcinoma, Hepatocellular 3 Melanoma 2 Endometrial Neoplasms 2 von Hippel-Lindau Disease 1 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Hematologic Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Adenoid Cystic 1 Brain Neoplasms 1 Bone Neoplasms 1 Advanced Malignancies 1 Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 1 Adenocarcinoma 1

Interventions

Cyclophosphamide 6 fludarabine 4 Standard of Care 4 Practice Guidelines as Topic 3 Mycophenolic Acid 3 GSK2636771 3 venetoclax 2 trametinib 2 talquetamab 2 osimertinib 2 dabrafenib 2 X-Rays 2 Whole-Body Irradiation 2 Thiotepa 2 Tacrolimus 2 Specimen Handling 2 Mesna 2 Melphalan 2 Magnetic Resonance Spectroscopy 2 Filgrastim 2 Biopsy 2 ulixertinib 1 trastuzumab biosimilar HLX02 1 thymoglobulin 1 sapanisertib 1 ruxolitinib 1 relatlimab 1 plerixafor 1 pertuzumab 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hematologic Neoplasms × lenvatinib × 30 days × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡